Keybanc analyst Brett Andress maintains Brunswick (NYSE:BC) with a Overweight and raises the price target from $85 to $88.
Psychedelics Biotech Companies Mark New Milestones In Drug Development Pipelines: Field Trip, Cybin and Wesana
On Tuesday, three public companies in the psychedelics/biotech space announced significant milestones in their drug development pipelines.